| Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress |
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – |
globenewswire.com |
2025-05-14 14:00:00 |
Czytaj oryginał (ang.) |
| Kura Oncology to Participate in Bank of America Securities Healthcare Conference |
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2025 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT on May 13, 2025. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event. |
globenewswire.com |
2025-05-06 11:30:00 |
Czytaj oryginał (ang.) |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 433,950 shares of common stock to sixteen (16) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-05-02 11:30:00 |
Czytaj oryginał (ang.) |
| Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript |
Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Troy Wilson – President and Chief Executive Officer Mollie Leoni – Chief Medical Officer Tom Doyle – Senior Vice President of Finance and Accounting Brian Powl – Chief Commercial Officer Conference Call Participants Jonathan Chang – Leerink Partners Salim Syed – Mizuho Cameron Bozdog – Bank of America Charles Zhu – LifeSci Capital Ellen Horste – TD Cowen Peter Lawson – Barclays David Dai – UBS Jeet Mukherjee – BTIG George Farmer – Scotiabank Roger Song – Jefferies Operator Good day everyone and welcome to today's First Quarter 2025 Kura Oncology Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-02 00:48:51 |
Czytaj oryginał (ang.) |
| Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates |
Kura Oncology (KURA) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.59 per share a year ago. |
zacks.com |
2025-05-01 22:30:52 |
Czytaj oryginał (ang.) |
| Kura Oncology Reports First Quarter 2025 Financial Results |
– NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2025 financial results and provided a corporate update. |
globenewswire.com |
2025-05-01 20:05:00 |
Czytaj oryginał (ang.) |
| Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST |
– Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure – |
globenewswire.com |
2025-04-28 11:30:00 |
Czytaj oryginał (ang.) |
| Kura Oncology to Report First Quarter 2025 Financial Results |
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. |
globenewswire.com |
2025-04-24 11:30:00 |
Czytaj oryginał (ang.) |
| Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA |
– Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation – – Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation – |
globenewswire.com |
2025-04-08 11:30:00 |
Czytaj oryginał (ang.) |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 79,500 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-04 11:30:00 |
Czytaj oryginał (ang.) |
| Kura Oncology to Participate in Stifel Targeted Oncology Forum |
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 10:30 a.m. ET / 7:30 a.m. PT on April 8, 2025. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event. |
globenewswire.com |
2025-04-01 11:30:00 |
Czytaj oryginał (ang.) |
| Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting |
– Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in patients with RCC in 2H 2025 – SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that an abstract containing preclinical data for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), in combination with cabozantinib, a tyrosine kinase inhibitor (TKI), in clear cell renal cell carcinoma (ccRCC), has been accepted for an oral presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL on April 29, 2025. “The latest findings for our next-generation farnesyl transferase inhibitor, KO-2806, being presented at this year's AACR Annual Meeting, add to the growing body of data demonstrating the potential of FTIs as companion therapeutic agents to augment the antitumor activities of various targeted therapies and to overcome resistance in combination,” said Francis Burrows, Ph.D. |
globenewswire.com |
2025-03-26 09:30:00 |
Czytaj oryginał (ang.) |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 190,000 shares of common stock to six (6) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-07 09:30:00 |
Czytaj oryginał (ang.) |
| Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity |
Kura Oncology's ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax's revumenib. Kura's strong cash position supports operations through 2027, bolstered by a lucrative deal with Kyowa Kirin, despite a 50/50 profit share. Market sentiment is low due to second-mover disadvantage and delayed catalysts, but current valuations present a potential buying opportunity. |
seekingalpha.com |
2025-03-04 12:12:45 |
Czytaj oryginał (ang.) |
| Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript |
Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Patti Bank - IR Troy Wilson - President and CEO Mollie Leoni - CMO Tom Doyle - SVP of Finance and Accounting Brian Powl - CCO Conference Call Participants Li Watsek - Cantor Fitzgerald Yen-Der Li - Leerink Partners Jason Zemansky - Bank of America Peter Lawson - Barclays Dara Azar - Stifel Charles Zhu - LifeSci Capital David Dai - UBS Justin Zelin - BTIG George Farmer - Scotiabank Operator Good day, everyone, and welcome to today's Q4 2024 Kura Oncology, Inc. Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-27 06:46:11 |
Czytaj oryginał (ang.) |
| Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates |
Kura Oncology (KURA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.55 per share a year ago. |
zacks.com |
2025-02-26 20:35:41 |
Czytaj oryginał (ang.) |
| Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results |
– KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial – – Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 – – Multiple data presentations for ziftomenib and pipeline programs expected throughout 2025 – – $727.4 million in cash, together with anticipated collaboration agreement payments, to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2024 financial results and provided a corporate update. |
globenewswire.com |
2025-02-26 18:03:00 |
Czytaj oryginał (ang.) |
| Kura Oncology to Participate in Three Upcoming Investor Conferences |
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences: |
globenewswire.com |
2025-02-25 09:30:00 |
Czytaj oryginał (ang.) |
| Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results |
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2024 financial results after the close of U.S. financial markets on Wednesday, February 26, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. |
globenewswire.com |
2025-02-19 09:30:00 |
Czytaj oryginał (ang.) |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 164,000 shares of common stock to nine (9) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-07 09:30:00 |
Czytaj oryginał (ang.) |